|
1
|
Leite JC, Gonçalves AAM, de Oliveira DS, Resende LA, Boas DFV, Ribeiro HS, Pereira DFS, da Silva AV, Mariano RMDS, Reis PCC, Nakasone EN, França-Silva JC, Galdino AS, Paes PRDO, Melo MM, Dias ES, Chávez-Fumagalli MA, da Silveira-Lemos D, Dutra WO, Giunchetti RC. Transmission-Blocking Vaccines for Canine Visceral Leishmaniasis: New Progress and Yet New Challenges. Vaccines (Basel) 2023; 11:1565. [PMID: 37896969 PMCID: PMC10610753 DOI: 10.3390/vaccines11101565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 09/17/2023] [Accepted: 09/19/2023] [Indexed: 10/29/2023] Open
Abstract
Dogs with visceral leishmaniasis play a key role in the transmission cycle of Leishmania infantum to humans in the urban environment. There is a consensus regarding the importance of developing a vaccine to control this disease. Despite many efforts to develop a protective vaccine against CVL, the ones currently available, Leish-tec® and LetiFend®, have limited effectiveness. This is due, in part, to the complexity of the immune response of the naturally infected dogs against the parasite and the complexity of the parasite transmission cycle. Thus, strategies, such as the development of a transmission-blocking vaccines (TBVs) already being applied to other vector-borne diseases like malaria and dengue, would be an attractive alternative to control leishmaniasis. TBVs induce the production of antibodies in the vertebrate host, which can inhibit parasite development in the vector and/or interfere with aspects of vector biology, leading to an interruption of parasite transmission. To date, there are few TBV studies for CVL and other leishmaniasis forms. However, the few studies that exist show promising results, thus justifying the further development of this approach.
Collapse
Affiliation(s)
- Jaqueline Costa Leite
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Ana Alice Maia Gonçalves
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Diana Souza de Oliveira
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Lucilene Aparecida Resende
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Diego Fernandes Vilas Boas
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Helen Silva Ribeiro
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Diogo Fonseca Soares Pereira
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Augusto Ventura da Silva
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Reysla Maria da Silveira Mariano
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Pedro Campos Carvalhaes Reis
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Eiji Nakasone Nakasone
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - João Carlos França-Silva
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Alexsandro Sobreira Galdino
- Microorganism Biotechnology Laboratory, Federal University of São João Del-Rei (UFSJ), Midwest Campus, Divinópolis 35501-296, MG, Brazil;
| | - Paulo Ricardo de Oliveira Paes
- Department of Veterinary Clinic and Surgery, School of Veterinary, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (P.R.d.O.P.); (M.M.M.)
| | - Marília Martins Melo
- Department of Veterinary Clinic and Surgery, School of Veterinary, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (P.R.d.O.P.); (M.M.M.)
| | - Edelberto Santos Dias
- René Rachou Research Center, Oswaldo Cruz Foundation, Belo Horizonte 30190-002, MG, Brazil;
| | - Miguel Angel Chávez-Fumagalli
- Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru;
| | - Denise da Silveira-Lemos
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Walderez Ornelas Dutra
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| | - Rodolfo Cordeiro Giunchetti
- Laboratory of Biology of Cell Interactions, Department of Morphology, Federal University of Minas Gerais (UFMG), Belo Horizonte 31270-901, MG, Brazil; (J.C.L.); (A.A.M.G.); (D.S.d.O.); (L.A.R.); (D.F.V.B.); (H.S.R.); (D.F.S.P.); (A.V.d.S.); (R.M.d.S.M.); (P.C.C.R.); (E.N.N.); (J.C.F.-S.); (D.d.S.-L.); (W.O.D.)
| |
Collapse
|
|
3
|
Das A, Ali N. Vaccine Development Against Leishmania donovani. Front Immunol 2012; 3:99. [PMID: 22615707 PMCID: PMC3351671 DOI: 10.3389/fimmu.2012.00099] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2012] [Accepted: 04/14/2012] [Indexed: 11/13/2022] Open
Abstract
Visceral leishmaniasis (VL) caused by Leishmania donovani and Leishmania infantum/chagasi represents the second most challenging infectious disease worldwide, leading to nearly 500,000 new cases and 60,000 deaths annually. Zoonotic VL caused by L. infantum is a re-emergent canid zoonoses which represents a complex epidemiological cycle in the New world where domestic dogs serve as a reservoir host responsible for potentially fatal human infection and where dog culling is the only measure for reservoir control. Life-long immunity to VL has motivated development of prophylactic vaccines against the disease but very few have progressed beyond the experimental stage. No licensed vaccine is available till date against any form of leishmaniasis. High toxicity and increasing resistance to the current chemotherapeutic regimens have further complicated the situation in VL endemic regions of the world. Advances in vaccinology, including recombinant proteins, novel antigen-delivery systems/adjuvants, heterologous prime-boost regimens and strategies for intracellular antigen presentation, have contributed to recent advances in vaccine development against VL. Attempts to develop an effective vaccine for use in domestic dogs in areas of canine VL should be pursued for preventing human infection. Studies in animal models and human patients have revealed the pathogenic mechanisms of disease progression and features of protective immunity. This review will summarize the accumulated knowledge of pathogenesis, immune response, and prerequisites for protective immunity against human VL. Authors will discuss promising vaccine candidates, their developmental status and future prospects in a quest for rational vaccine development against the disease. In addition, several challenges such as safety issues, renewed and coordinated commitment to basic research, preclinical studies and trial design will be addressed to overcome the problems faced in developing prophylactic strategies for protection against this lethal infection.
Collapse
Affiliation(s)
- Amrita Das
- Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology Kolkata, India
| | | |
Collapse
|
|
5
|
Coutinho-Abreu IV, Ramalho-Ortigao M. Transmission blocking vaccines to control insect-borne diseases: a review. Mem Inst Oswaldo Cruz 2010; 105:1-12. [PMID: 20209323 DOI: 10.1590/s0074-02762010000100001] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2009] [Accepted: 12/17/2009] [Indexed: 11/22/2022] Open
Abstract
Insect-borne diseases are responsible for severe mortality and morbidity worldwide. As control of insect vector populations relies primarily on the use of insecticides, the emergence of insecticide resistance as well to unintended consequences of insecticide use pose significant challenges to their continued application. Novel approaches to reduce pathogen transmission by disease vectors are been attempted, including transmission-blocking vaccines (TBVs) thought to be a feasible strategy to reduce pathogen burden in endemic areas. TBVs aim at preventing the transmission of pathogens from infected to uninfected vertebrate host by targeting molecule(s) expressed on the surface of pathogens during their developmental phase within the insect vector or by targeting molecules expressed by the vectors. For pathogen-based molecules, the majority of the TBV candidates selected as well as most of the data available regarding the effectiveness of this approach come from studies using malaria parasites. However, TBV candidates also have been identified from midgut tissues of mosquitoes and sand flies. In spite of the successes achieved in the potential application of TBVs against insect-borne diseases, many significant barriers remain. In this review, many of the TBV strategies against insect-borne pathogens and their respective ramification with regards to the immune response of the vertebrate host are discussed.
Collapse
Affiliation(s)
- Iliano V Coutinho-Abreu
- Biology of Disease Vectors Laboratory, Department of Entomology, Kansas State University, Manhattan, KS 66506, USA
| | | |
Collapse
|
|
6
|
Kavoosi G, Ardestani SK, Kariminia A, Alimohammadian MH. Leishmania major lipophosphoglycan: discrepancy in Toll-like receptor signaling. Exp Parasitol 2009; 124:214-8. [PMID: 19769970 DOI: 10.1016/j.exppara.2009.09.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2009] [Revised: 09/16/2009] [Accepted: 09/16/2009] [Indexed: 10/20/2022]
Abstract
Lipophosphoglycan (LPG) is structurally characterized by a series of phosphoglycan repeat units. Cellular LPG, isolated from promastigotes, has a very similar structure to culture supernatant LPG, but differs in the average number of phosphorylated oligosaccharide repeat units and in glycan composition. Comparison of these LPGs with capillary electrophoresis and immunoblotting indicate that these molecules are highly conserved structurally and composed of galactosylated Gal-Man repeats but their size and molecular weight are very different which is due to glycan portion. There are 30 and 20 repeat units in sLPG and mLPG, respectively. Both LPGs induced nitric oxide in macrophages cell line while sLPG had the higher stimulatory effect. In the presence of anti-TLR2 nitric oxide stimulated by LPG was reduced to control levels. In addition, in the presence of anti-TLR4, nitric oxide stimulated by LPGs was not affected. We propose that lipophosphoglycan induces nitric oxide production via TLR2 signaling pathway.
Collapse
|
|
7
|
Kavoosi G, Ardestani SK, Kariminia A, Abolhassani M, Turco SJ. Leishmania major: Reactive oxygen species and interferon gamma induction by soluble lipophosphoglycan of stationary phase promastigotes. Exp Parasitol 2006; 114:323-8. [PMID: 16759653 DOI: 10.1016/j.exppara.2006.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2006] [Revised: 04/17/2006] [Accepted: 04/24/2006] [Indexed: 11/27/2022]
Abstract
Protozoan parasites of the genus Leishmania cause a number of important human diseases. One of the key determinants of parasite infectivity and survival is membrane glycoconjugate lipophosphoglycan (mLPG). In addition, it has been shown that mLPG could be used as a transmission blocking vaccine. Since culture supernatant of parasite promastigotes is a good source of LPG, we attempted to compare the immunological properties of culture supernatant and membrane LPG prepared from stationary phase promastigotes of Leishmania major. The purity of supernatant LPG (sLPG) and membrane LPG (mLPG) was determined by thin layer chromatography. The effect of sLPG and mLPG on the production of reactive oxygen species (ROS) was studied using PBMCs isolated from healthy individuals. In addition, induction of IL-12, IFN-gamma and IL-10 secretion in the presence of sLPG and mLPG was investigated. Reactive oxygen species in addition to IL-10 and IL-12 were induced by both sLPG and mLPG. However, IFN-gamma production was promoted only in response to sLPG suggesting its ability to promote Th1 response and implication in vaccine design.
Collapse
Affiliation(s)
- Gholamreza Kavoosi
- Institute of Biochemistry and Biophysics, University of Tehran, P.O.Box 13148-1384, Tehran, Iran
| | | | | | | | | |
Collapse
|
|
9
|
Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LOP, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG, de Oliveira SM, Palatnik-de-Sousa CB. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 2005; 24:2423-31. [PMID: 16386824 DOI: 10.1016/j.vaccine.2005.11.061] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2005] [Accepted: 11/29/2005] [Indexed: 11/26/2022]
Abstract
Transmission blocking vaccines are one of the control strategies for vector-transmitted protozoan diseases. Antibodies raised in the vaccinated host prevent the development of the parasite in the insect vector, interrupting the epidemiological cycle. The FML antigen of Leishmania donovani in combination with saponin (FML-vaccine and Leishmune) induced 92-97% of protections against zoonotic visceral leishmaniasis. We assayed the ability of FML to inhibit Leishmania donovani and Leishmania chagasi procyclic promastigote-binding to dissected Lutzomyia longipalpis midguts. We found a dose-dependent inhibition, more pronounced on L. donovani (80%) than on L. chagasi promastigotes (p<0.001). On the other hand, the Fab-IgG serum fraction of Leishmune vaccinated dogs (IgG2 predominant), also inhibited parasite binding in a dose-response (p<0.0001) with an equally potent effect against L. donovani or L. chagasi (p = 0.061). The transmission blocking properties of the Leishmune vaccine was also assessed by an in vivo membrane assay, with sand flies fed with 1.5 x 10(7) amastigotes, human blood and, vaccinated or normal control dog sera. Significantly higher values were found in rate of infection (p<0.025) and intensity of infection (number of parasites/insect) (p<0.05) of control sand flies, making a very reduced infection index (20.7%) in the vaccine group. Our results disclosed that the Leishmune vaccine is a TBV, and that the dog antibodies present in sera, even 12 months after vaccination, lead to a significant effective protection of 79.3%.
Collapse
Affiliation(s)
- Elvira M Saraiva
- Instituto de Microbiologia, Prof. Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Ilha do Fundão, Caixa Postal 68040, CEP 21941-590, Rio de Janeiro, RJ, Brazil
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|